Tech Company Financing Transactions

Triumvira Immunologics Funding Round

B Capital Group, ATEM Capital and Leaps by Bayer participated in a $100 million Series A funding round for Triumvira Immunologics. The financing round was announced on 3/17/2022.

Transaction Overview

Announced On
3/17/2022
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Crystal Mountain At Barton Creek
Austin, TX 78733
USA
Email Address
Overview
Triumvira Immunologics, Inc. (Triumvira) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
Profile
Triumvira Immunologics LinkedIn Company Profile
Social Media
Triumvira Immunologics Company Twitter Account
Company News
Triumvira Immunologics News
Facebook
Triumvira Immunologics on Facebook
YouTube
Triumvira Immunologics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Paul Lammers
  Paul Lammers LinkedIn Profile  Paul Lammers Twitter Account  Paul Lammers News  Paul Lammers on Facebook
Chief Medical Officer
Sabine Chlosta
  Sabine Chlosta LinkedIn Profile  Sabine Chlosta Twitter Account  Sabine Chlosta News  Sabine Chlosta on Facebook
Chief Scientific Officer
Jonathan Bramson
  Jonathan Bramson LinkedIn Profile  Jonathan Bramson Twitter Account  Jonathan Bramson News  Jonathan Bramson on Facebook
Chief Technical Officer
Donna Rill
  Donna Rill LinkedIn Profile  Donna Rill Twitter Account  Donna Rill News  Donna Rill on Facebook
VP - Bus. Development
Joshua Carle
  Joshua Carle LinkedIn Profile  Joshua Carle Twitter Account  Joshua Carle News  Joshua Carle on Facebook
VP - Finance
Jon Irvin
  Jon Irvin LinkedIn Profile  Jon Irvin Twitter Account  Jon Irvin News  Jon Irvin on Facebook
VP - R & D
Andreas Bader
  Andreas Bader LinkedIn Profile  Andreas Bader Twitter Account  Andreas Bader News  Andreas Bader on Facebook
VP - Regulatory Affairs
Cynthia Molina
  Cynthia Molina LinkedIn Profile  Cynthia Molina Twitter Account  Cynthia Molina News  Cynthia Molina on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/17/2022: Getir venture capital transaction
Next: 3/17/2022: HUBUC venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to record all VC transactions involving tech companies. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary